Wikipedia

Basilea Pharmaceutica

Basilea Pharmaceutica is a biopharmaceutical company based in Allschwil near Basel, Switzerland.[4] Basilea was spun off from F. Hoffmann-La Roche in 2000 and has been listed as an independent company on the Swiss stock exchange since March 2004.[5] The company's subsidiary is Basilea Pharmaceutica International AG, Allschwil, which is also based in Allschwil, Switzerland, and in which the company's operating activities are bundled.[6]

Basilea Pharmaceutica AG, Allschwil
Company typePublic
SIX: BSLN
IndustryPharmaceutical industry
Founded2000
HeadquartersAllschwil, Switzerland
Key people
David Veitch (Chief Executive Officer)[1]
Domenico Scala (Chairman of the Board][2]
ProductsIsavuconazole, Ceftobiprole
RevenueCHF 157.6 million (2023)[3]
Number of employees
147 (2023)[3]
Websitewww.basilea.com

History

edit

Basilea Pharmaceutica was founded in 2000 as a corporate spin-off of the pharmaceutical company Roche.[5]

In 2002, Chinese subsidiary Basilea Pharmaceutica China Ltd. (BPC) was founded and was located in the Haimen Economic and Technological Development Zone in the city of Nantong in the Chinese province of Jiangsu, north of Shanghai.[7]

With the listing on the Swiss stock exchange in March 2004 at a price of CHF 98 per share, Basilea realised gross proceeds of more than CHF 200 million.[8]

In 2012, Basilea sold the worldwide rights to Toctino, a dermatology drug developed by Basilea that was approved and marketed in various European countries in 2008, to Stiefel Labs, a subsidiary of the British pharmaceutical company GlaxoSmithKline, for CHF 216 million.[9]

At the beginning of 2013, Basilea received orphan drug status in the USA for the antifungal drug Isavuconazole for the treatment of invasive fungal infections, which at the time, analysts estimated to be worth up to CHF 150 million per year.[10][11] Isavuconazole was developed in phase III in conjunction with pharmaceutical company Astellas Pharma.[12] In March 2015, Isavuconazole was approved in the US, followed by the entire EU in October of the same year.[13][14] In the following years, the drug was also approved in Japan, several Eurasian countries, Australia and China.[15]

In October 2013, Basilea received marketing authorisation in twelve European countries, including Germany, for the distribution of the broad-spectrum antibiotic Ceftobiprole for the treatment of bacterial lung infections;[16][17] in the following two years, the drug was gradually approved in other European countries and non-EU countries.[18][19] Ceftobiprole has been approved in 32 countries and has been marketed in 21 countries since the end of 2023.[19][20]

In 2020, Basilea sold the group headquarters in Basel to the pension fund of the Swiss bank UBS by way of a sale-leaseback and moved to its new headquarters in Allschwil in mid-2022.[21][22] The gross proceeds from the sale amounted to around CHF 19 million before fees and transaction costs.[22] In 2021, Basilea Pharmaceutica China Ltd. was sold to the US company PHT International.[23] Basilea was previously active in oncological research, but withdrew from it at the beginning of 2022 and has since been focusing purely on anti-infectives.[15][24] In 2023, Basilea acquired the rights to the antifungal drug Fosmanogepix from Pfizer.[25]

By the end of 2023, Isavuconazole was commercialised in more than 70 countries, including the United States, most EU countries, China and Japan. Isavuconazole's total global sales in the twelve-month period between October 2022 and September 2023 amounted to CHF 406 million. This corresponds to growth of 22 per cent compared to the previous year.[26]

In early April 2024, the US Food and Drug Administration (FDA) approved Ceftobiprole for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia) and for adult patients with right-sided infective endocarditis. In addition, the FDA approved Ceftobiprole for the treatment of acute bacterial skin and skin structure infections in adult patients and in adult and pediatric patients aged three months to less than 18 years with community-acquired bacterial pneumonia (CAPB).[27]

Corporate structure

edit

In the financial year 2023, Basilea Pharmaceutica AG, Allschwil generated company sales of CHF 157.6 million and employed 147 people.[3] Since the 2022 financial year, Basilea has consistently been generating operating and net profits.[28][29]

In addition to its headquarters in Allschwil, Switzerland,[4] Basilea is represented by subsidiaries in the UK and Germany.[30]

Basilea cooperates with licence and distribution partners in over 100 countries.[31]

Products

edit

The company's research and development activities are focused on drugs for the treatment of severe, resistant bacterial infections and life-threatening, invasive fungal diseases.[11][32][33]

Basilea's products are aimed at diseases that have so far been insufficiently treatable.[34] The company markets the following products exclusively through licence and distribution partners:[15]

Ceftobiprole (trade name Zevtera/Mabelio) is a broad-spectrum antibiotic administered intravenously for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) in adults. It has an active effect against the bacterium Staphylococcus aureus (MRSA), including methicillin-resistant strains, and against penicillin-resistant Streptococcus pneumoniae (PRSP) bacteria, as well as against gram-negative pathogens such as Enterobacteriaceae.[17][35][36]

Isavuconazole (trade name Cresemba) is an intravenous and oral antifungal agent for the treatment of patients with invasive aspergillosis and invasive mucormycosis.[37]

While Astellas is responsible for the commercialisation of Cresemba in the USA,[38] the pharmaceutical group Pfizer covers the commercialisation in most of Europe[39] and also distributes Cresemba in China and the Asia–Pacific (APAC) area.[40] Basilea's distribution partner in the MENA region is Hikma Pharmaceuticals LLC;[41] Knight Therapeutics Inc. commercialises the antifungal Cresemba in South America.[42]

References

edit
  1. ^ "David Veitch: Chief Executive Officer, Basilea Pharmaceutica AG". Bloomberg. 2023. Retrieved 2024-07-21.
  2. ^ "Domenico Scala wird Davidoff-Präsident: Vom Fifa-Reformer zum Zigarren-Boss". Blick. 2018-09-12. Retrieved 2024-07-21.
  3. ^ a b c Full-Year Report 2023, published in Public Now, 12 February 2024, retrieved 12 April 2024.
  4. ^ a b "US pays Basel pharma firm to develop new antibiotic". SWI swissinfo.ch. 2016-04-20. Retrieved 2024-07-20.
  5. ^ a b "Basilea nähert sich der Gewinnzone". Handelszeitung. 27 february 2018.
  6. ^ "Firmenprofil: Basilea Pharmaceutica International AG, Allschwil". Dun & Bradstreet. 2 January 2024.
  7. ^ "Basilea Pharmaceutica China Ltd.: Company Profile". Echemi.com. Retrieved 2024-07-20.
  8. ^ Paul Verbraeken: "Nebenwerte Basilea: Intakte Wachstumsstory". Handelszeitung. 25 May 2019.
  9. ^ Ruedi Mäder: "Basilea hat einen Partner gefunden: Tochter von GlaxoSmithKline bezahlt über 200 Millionen für Mittel gegen Ekzeme". Basler Zeitung. 13 June 2012.
  10. ^ Felix Erbacher: "Dollar und mildes Umfeld schüren Erwartungen: Auf die Rapporte von Clariant und Actelion reagieren die Anleger diese Woche erwartungsvoll". Basler Zeitung. 21 february 2015.
  11. ^ a b "Gute Nachricht für Basilea: US-Arzneimittelbehörde gibt positiven Zwischenbefund ab". Basler Zeitung. 4 december 2013.
  12. ^ "Basilea in neuer Partnerschaft: Vermarktung von neuem Antipilzmittel". Basler Zeitung. 25 february 2010.
  13. ^ "Vermarktungsrecht in der EU für Mittel gegen Pilzinfektionen". Nordwestschweiz. 24 October 2015.
  14. ^ "Basilea erhält weitere Meilensteinzahlung von Pfizer". Finanz und Wirtschaft. 2023-11-20. Retrieved 2024-07-20.
  15. ^ a b c Boyadjian, Rupen (2023-06-06). "Basilea von Ungewissheiten gebremst". Finanz und Wirtschaft. Retrieved 2024-07-20.
  16. ^ Viola, Axel (2014-06-03). "Nosokomiale Pneumonie: Neues Cephalosporin bessert schneller die Symptomatik". Medscape. Retrieved 2023-01-10.
  17. ^ a b "Basilea antibiotic to treat pneumonia wins European backing". Reuters. Retrieved 2024-07-20.
  18. ^ "Basilea mit höherem Verlust wegen Kosten für Markteinführung". Basler Zeitung. 2015-02-17. Retrieved 2024-07-20.
  19. ^ a b Romanoff, Soo (2024-04-04). "Basilea Pharmaceutica — Zevtera crosses key US regulatory hurdle". Edison Group. Retrieved 2024-07-21.
  20. ^ "Finding future medicines". Annual Report: 39. 2023 – via Basilea Pharmaceutica Ltd.
  21. ^ "Basilea gibt den Umzug des Firmensitzes nach Allschwil, Kanton Basel-Landschaft, für das Jahr 2022 bekannt". boerse.de. 2020-06-30. Retrieved 2024-07-21.
  22. ^ a b "Basilea enters into sale and leaseback agreement for corporate headquarters building". Yahoo! Finance. 2020-06-23. Retrieved 2024-07-20.
  23. ^ "Bankaktien sind gefragt". Finanz und Wirtschaft. 17 february 2021.
  24. ^ "Basilea sieht sich auf Kurs, ein führendes Antiinfektiva-Unternehmen zu werden". Finanz und Wirtschaft. 6 january 2024.
  25. ^ Spieler, Martin (2024-04-15). "Nicht von falschen Dividendenerwartungen blenden lassen". Tages-Anzeiger (in German). Retrieved 2024-07-22.
  26. ^ "Basilea provides portfolio status update". Yahoo! Finance. 2024-01-05. Retrieved 2024-07-21.
  27. ^ "FDA Approves New Antibiotic for Three Different Uses". Food and Drug Administration. 2024-04-03. Retrieved 2024-07-22.
  28. ^ Boyadjian, Rupen (2023-01-24). "Basilea erreicht vorzeitig die Gewinnschwelle". Finanz & Wirtschaft. Retrieved 2024-07-21.
  29. ^ "GNW-Adhoc: Basilea präsentiert nach erfolgreich implementierter neuer Strategie starke Finanzergebnisse für 2022". Börse online. 2023-02-14. Retrieved 2024-07-21.
  30. ^ Valentin Handschin: «"Breakeven ist nicht vor 2011 möglich"». Handelszeitung. 23 april 2008.
  31. ^ "Basilea Pharmaceutica Aktie". boerse.de. 2023. Retrieved 2024-07-21.
  32. ^ "Besserer Ausblick und mögliche US-Zulassung stützen Basilea-Kurs". Sonntagszeitung. 24 September 2023.
  33. ^ "Die Antibiotika-Champions aus Allschwil". Basler Zeitung. 15 february 2023.
  34. ^ "Auf Resistenzen konzentriert". Ärzte-Zeitung. 22 June 2010.
  35. ^ "Basileas europäischer Zulassungsantrag für Ceftobiprol zur Behandlung von Lungenentzündung zur Prüfung angenommen". Hamburger Abendblatt. 5 October 2012.
  36. ^ "Basilea nähert sich der Gewinnzone". Handelszeitung. 27 february 2018.
  37. ^ "Neues Antimykotikum Cresemba: Einführung in Deutschland". Deutsches Ärzteblatt. 2016. Retrieved 2024-07-21.
  38. ^ "Basilea auf dem Weg zu dauerhaft schwarzen Zahlen Schweiz: Das Biotech-Unternehmen rechnet für 2020 mit weniger Verlust als im Vorjahr. Die liquiden Mittel werden deutlich höher sein als angenommen". Finanz und Wirtschaft. 12 August 2020.
  39. ^ "Pfizer übernimmt Vertrieb von Cresemba". DAZ Online. 2017-07-21. Retrieved 2024-07-21.
  40. ^ "Nestlé-Aktie und Co.: Die fünf Schweizer Top-Empfehlungen von Julius Bär". Börse Online. 2018-02-20. Retrieved 2024-07-22.
  41. ^ "Basilea reports on first Cresemba approval in MENA region". Swiss Biotech Association. 2018-08-13. Retrieved 2024-07-21.
  42. ^ "Basilea Pharmaceutica to receive first milestone payment on Cresemba sales in Latin America from Knight Therapeutics". Pharmabiz.com. 2024-01-22. Retrieved 2024-07-21.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Basilea_Pharmaceutica&oldid=1236375244"